Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0SY6C
|
|||
| Former ID |
DNC010805
|
|||
| Drug Name |
7,4'-Dihydroxyflavone
|
|||
| Synonyms |
7,4'-Dihydroxyflavone; 4',7-Dihydroxyflavone; 2196-14-7; 7-Hydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one; 4H-1-Benzopyran-4-one, 7-hydroxy-2-(4-hydroxyphenyl)-; FLAVONE, 4',7-DIHYDROXY-; UNII-53ZZF57X0U; CHEMBL294878; 53ZZF57X0U; 7-hydroxy-2-(4-hydroxyphenyl)chromen-4-one; CHEBI:29503; LCAWNFIFMLXZPQ-UHFFFAOYSA-N; BRN 0224356; PubChem9844; AC1NQZG5; 7, 4'-Dihydroxyflavone; Spectrum4_001280; 7,4''-Dihydroxyflavone; 7,4' - Dihydroxyflavone; C12123; 7,4&#39-dihydroxyflavone; KBioGR_001900; SPECTRUM1500721; SCHEMBL157723
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C15H10O4
|
|||
| Canonical SMILES |
C1=CC(=CC=C1C2=CC(=O)C3=C(O2)C=C(C=C3)O)O
|
|||
| InChI |
1S/C15H10O4/c16-10-3-1-9(2-4-10)14-8-13(18)12-6-5-11(17)7-15(12)19-14/h1-8,16-17H
|
|||
| InChIKey |
LCAWNFIFMLXZPQ-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 2196-14-7
|
|||
| PubChem Compound ID | ||||
| ChEBI ID |
CHEBI:29503
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Aromatase (CYP19A1) | Target Info | Inhibitor | [1] |
| BioCyc | Superpathway of steroid hormone biosynthesis | |||
| Estradiol biosynthesis II | ||||
| Estradiol biosynthesis I | ||||
| KEGG Pathway | Steroid hormone biosynthesis | |||
| Metabolic pathways | ||||
| Ovarian steroidogenesis | ||||
| NetPath Pathway | FSH Signaling Pathway | |||
| Panther Pathway | Androgen/estrogene/progesterone biosynthesis | |||
| Pathwhiz Pathway | Androgen and Estrogen Metabolism | |||
| Reactome | Endogenous sterols | |||
| WikiPathways | Metapathway biotransformation | |||
| Tryptophan metabolism | ||||
| Oxidation by Cytochrome P450 | ||||
| Ovarian Infertility Genes | ||||
| Metabolism of steroid hormones and vitamin D | ||||
| FSH signaling pathway | ||||
| Integrated Breast Cancer Pathway | ||||
| Phase 1 - Functionalization of compounds | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19). Bioorg Med Chem Lett. 2010 May 15;20(10):3050-64. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.